Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized contr... by Peter McAllister, Paul K. Winner, Jessica Ailani, Dawn C. Buse, Richard B. Lipton, George Chakhava, Mette Krog Josiassen, Annika Lindsten, Lahar Mehta, Anders Ettrup, Roger Cady

Subjects: Get full text

Shift in diagnostic classification of migraine after initiation of preventive treatment with eptinezumab: post hoc analysis of the PROMISE studies by Patricia Pozo-Rosich, David W. Dodick, Anders Ettrup, Joe Hirman, Roger Cady

Subjects: Get full text

Efficacy and safety of eptinezumab for migraine: A systematic review and meta-analysis by Yi Zhong, Jiahe Wang, Hang Li, Siyuan Yang, Xiang Li, Heng Gao, Gang Chen

Subjects: Get full text

Cardiovascular outcomes in adults with migraine treated with eptinezumab for migraine prevention: pooled data from four randomized, double-blind, placebo-controlled studies by Timothy R. Smith, Egilius L. H. Spierings, Roger Cady, Joe Hirman, Anders Ettrup, Vivienne Shen

Subjects: “…Eptinezumab…”
Get full text

Eptinezumab for the Prevention of Migraine: Clinical Utility, Patient Preferences and Selection – A Narrative Review by Altamura C, Brunelli N, Marcosano M, Alesina A, Fofi L, Vernieri F

Subjects: “…eptinezumab…”
Get full text

Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial by Jessica Ailani, Peter McAllister, Paul K. Winner, George Chakhava, Mette Krog Josiassen, Annika Lindsten, Bjørn Sperling, Anders Ettrup, Roger Cady

Subjects: “…Eptinezumab…”
Get full text

Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety... by Stephen Silberstein, Merle Diamond, Nada A. Hindiyeh, David M. Biondi, Roger Cady, Joe Hirman, Brent Allan, Susan Pederson, Barbara Schaeffler, Jeff Smith

Subjects: “…Eptinezumab…”
Get full text

Optimization of acute medication use following eptinezumab initiation during a migraine attack: post hoc analysis of the RELIEF study by Roger Cady, Richard B. Lipton, Dawn C. Buse, Mette Krog Josiassen, Annika Lindsten, Anders Ettrup

Subjects: Get full text

Improving to Four or Fewer Monthly Headache Days Per Month Provides a Clinically Meaningful Therapeutic Target for Patients with Chronic Migraine by Robert G. Kaniecki, Deborah I. Friedman, Divya Asher, Joe Hirman, Roger Cady

Subjects: Get full text

Tolerability of eptinezumab in overweight, obese or type 1 diabetes patients by Brian Baker, Barbara Schaeffler, Joe Hirman, Marcus Hompesch, Susan Pederson, Jeff Smith

Subjects: “…eptinezumab…”
Get full text

Effectiveness and Safety of Eptinezumab in Episodic and Chronic Migraine Headache in the UAE: A Retrospective Study by Yazan Bader, Reem Suliman, Mohamad Harb, Vanessa Santos, Ibrahim Al Qaisi, Taoufik Alsaadi

Subjects: “…Eptinezumab…”
Get full text

Improvement of comorbid anxiety and depression in patients with migraine treated with injectable preventive calcitonin gene-related peptide antagonists: Review of clinical evidence by Abubker Omaer, Abdulrazaq Albilali, Reem Bamogaddam, Fares Almutairi, Raghad Alsaif, Osama Almohammadi, Abdullah A Alhifany

Subjects: “…Eptinezumab…”
Get full text

Different dosage regimens of Eptinezumab for the treatment of migraine: a meta-analysis from randomized controlled trials by Zeya Yan, Tao Xue, Shujun Chen, Xin Wu, Xingyu Yang, Guangjie Liu, Shan Gao, Zhouqing Chen, Zhong Wang

Subjects: “…Eptinezumab…”
Get full text

Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial by David Kudrow, Roger K. Cady, Brent Allan, Susan M. Pederson, Joe Hirman, Lahar R. Mehta, Barbara A. Schaeffler

Subjects: “…Eptinezumab…”
Get full text

Impact of eptinezumab on work productivity beyond reductions in monthly migraine days: post hoc analysis of the DELIVER trial by Piero Barbanti, Susanne F. Awad, Heather Rae-Espinoza, Stephane A. Regnier, Xin Ying Lee, Peter J. Goadsby

Subjects: Get full text

Managing Migraine: Medication Overuse Headache and Treatment with Eptinezumab by Nicole Limberg

Subjects: Get full text

Patient-reported outcomes, health-related quality of life, and acute medication use in patients with a ≥ 75% response to eptinezumab: subgroup pooled analysis of the PROMISE trials... by Richard B. Lipton, Larry Charleston, Cristina Tassorelli, Thomas Brevig, Joe Hirman, Roger Cady

Subjects: “…Eptinezumab…”
Get full text

Eptinezumab Demonstrated Efficacy Regardless of Prior Preventive Migraine Treatment Failure Type: Post Hoc Analyses of the DELIVER Study by Patricia Pozo-Rosich, Messoud Ashina, Stewart J. Tepper, Sidsel Jensen, Line Pickering Boserup, Mette Krog Josiassen, Bjørn Sperling

Subjects: Get full text

Measuring dose-related efficacy of eptinezumab for migraine prevention: post hoc analysis of PROMISE-1 and PROMISE-2 by Rami Apelian, Lee Boyle, Joe Hirman, Divya Asher

Subjects: “…Eptinezumab…”
Get full text

Early clinical experience with eptinezumab: results of a retrospective observational study of patient response in the United States by Amaal J. Starling, Steven Kymes, Divya Asher, Seema Soni-Brahmbhatt, Meghana Karnik-Henry

Subjects: “…Eptinezumab…”
Get full text